Fundraising FoxNGN NextGen Investment — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Hypercell Technologieshypercelltechnologies.cominSep 2026SEC filingmedium confidence
Hypercell develops rapid on-site diagnostic tests that detect pathogens such as Salmonella and E. coli in the food supply chain, aiming to deliver both speed and lab-grade accuracy.
BiotechFoodTechHealthtechMedical DevicesBrookhaven, US
Brian McFarlane(Chief Commercial Officer)inLoïc Deblais(Chief Science Officer)inSam Jactel(Co-founder & Senior Advisor)inBruno Jactel(Founder)inJames Cali(Director)Tony Puri(Director)
Board seatJames Cali· per SEC Form D · $4.4M raise · filed Oct 2026
Co-investorsSerra VenturesSOSV
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.